Get the Stockscreener App
64.11
0.63%
-0.5782
Exact Sciences Corp stock is traded at $64.11, with a volume of 613.05K.
It is down -0.63% in the last 24 hours and up +13.33% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$64.69
Open:
$64.9
24h Volume:
613.05K
Relative Volume:
0.22
Market Cap:
$12.16B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-11.64
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
+1.23%
1M Performance:
+13.33%
6M Performance:
+24.69%
1Y Performance:
-7.91%
1-Day Range:
$64.17
$65.59
1-Week Range:
$62.39
$65.59
52-Week Range:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
64.25 | 12.25B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
558.72 | 213.17B | 43.74B | 6.59B | 6.11B | 17.30 |
|
DHR
Danaher Corp
|
213.00 | 152.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
734.01 | 50.36B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
143.07 | 41.49B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
209.53 | 36.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences (EXAS) Q3 Earnings Preview: Positive Revisions Bo - GuruFocus
Exact Sciences Corporation Stock (EXAS) Opinions on Upcoming Earnings and Clinical Data - Quiver Quantitative
Should You Buy Exact Sciences Stock Before Nov. 3? - AOL.com
Nisa Investment Advisors LLC Acquires 4,500 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (EXAS) Reports Q3: Everything You Need To Know Ahead Of Earnings - Yahoo! Finance UK
Exact Sciences Corporation (EXAS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
EXACT SCIENCES Earnings Preview: Recent $EXAS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Exact Sciences Corporation $EXAS Shares Sold by Jennison Associates LLC - MarketBeat
Brighton Jones LLC Takes $366,000 Position in Exact Sciences Corporation $EXAS - MarketBeat
KLCM Advisors Inc. Invests $212,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences pulls out of major expansion project near Phoenix Sky Harbor - azcentral.com and The Arizona Republic
Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection - MSN
Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer - MSN
69,932 Shares in Exact Sciences Corporation $EXAS Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Why Exact Sciences Corporation stock could see breakout soon2025 Market Trends & Expert Curated Trade Ideas - newser.com
Can Exact Sciences Corporation (EXK) stock hit consensus price targetsTrade Ideas & Daily Stock Momentum Reports - newser.com
One-on-One with David Harding of Exact Sciences - Modern Healthcare
A Look at Exact Sciences’s Valuation as New Cancer Screening Advances Debut at Major Gastroenterology Meeting - Yahoo Finance
Can Exact Sciences Corporation (EXK) stock stage a strong rebound this quarterIPO Watch & Daily Profit Maximizing Tips - newser.com
Zanotti of Exact Sciences sells $780k in stock By Investing.com - Investing.com UK
Leading vs lagging indicators on Exact Sciences Corporation performance2025 Performance Recap & Real-Time Chart Breakout Alerts - newser.com
Exact Sciences presents new colorectal cancer screening data at ACG By Investing.com - Investing.com Philippines
Is Exact Sciences Corporation stock a buy in volatile markets2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Insider Sell: Katherine Zanotti Sells 12,000 Shares of Exact Sci - GuruFocus
Zanotti of Exact Sciences sells $780k in stock - Investing.com
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
Exact Sciences Corp Director Katherine S Zanotti Sells 12,000 Shares - TradingView
Exact Sciences (MEX:EXAS) Other Stockholders Equity : MXN-0 Mil (As of Jun. 2025) - GuruFocus
How Exact Sciences Corporation (EXK) stock reacts to fiscal policiesQuarterly Risk Review & Low Risk High Reward Ideas - newser.com
Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Exact Sciences presents new colorectal cancer screening data at ACG - Investing.com
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps - The Globe and Mail
Peregrine Capital Management LLC Acquires 117,331 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Will Exact Sciences Corporation (EXK) stock announce special dividendJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Is Exact Sciences Corporation stock a buy for dividend growthWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com
Can Exact Sciences Corporation stock deliver surprise earnings beatJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):